Review Article

Placental Vacuolar ATPase Function Is a Key Link between Multiple Causes of Preeclampsia

Dongxin Zhang, 1 Duyun Ye, 1 and Hongxiang Chen 2,3

1 Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, No. 13, Hangkong Road, Wuhan 430030, China
2 Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3 Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA

Correspondence should be addressed to Duyun Ye; yedy@mails.tjmu.edu.cn

Received 28 March 2013; Accepted 15 April 2013

Copyright © 2013 Dongxin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Preeclampsia, a relatively common pregnancy disorder, is one of the major causes of maternal and fetal morbidity and mortality. Despite numerous research, the etiology of this syndrome remains not well understood as the pathogenesis of preeclampsia is complex, involving interaction between genetic, immunologic, and environmental factors. Preeclampsia, originating in placenta abnormalities, is induced by the circulating factors derived from the abnormal placenta. Recent work has identified various molecular mechanisms related to placenta development, including renin-angiotensin system, 1,25-dihydroxyvitamin D, and lipoxin A4. Interestingly, advances suggest that vacuolar ATPase, a key molecule in placentation, is closely associated with them. Therefore, this intriguing molecule may represent an important link between various causes of preeclampsia. Here, we review that vacuolar ATPase works as a key link between multiple causes of preeclampsia and discuss the potential molecular mechanisms. The novel findings outlined in this review may provide promising explanations for the causation of preeclampsia and a rationale for future therapeutic interventions for this condition.

1. Preeclampsia

Preeclampsia, a pregnancy-complicated syndrome, is one of the leading causes of maternal and fetal morbidity and mortality [1]. This potentially dangerous condition affects approximately 2–7% of all pregnancies in the western world, but the incidence in developing countries can be greater [1, 2]. Preeclampsia is a maternal systemic symptom of late second or third trimester of pregnancy, characterized by hypertension, proteinuria, fetal intrauterine growth restriction, and other maternal abnormality [3]. In the worst cases, it may threaten the survival of both mother and baby [4]. Now, except for induced delivery, there is no effective treatment to cure it. Risk factors involved in preeclampsia have been increasingly identified (Table 1), and emergence of any risk factor may cause a woman to develop preeclampsia. However, exact pathogenesis of this disorder remains uncertain since numerous research into the etiology of preeclampsia did not progress significantly. Understanding the detailed mechanism underlying preeclampsia will help to develop novel prophylactic and therapeutic interventions for this condition.

The current understanding about preeclampsia is that it appears to develop in a two-stage progress, with a preclinical initial stage which has an abnormal placenta, followed by a second stage during which release of soluble factors from hypoxic placenta leads to various observed maternal conditions, including hypertension, proteinuria, and generalized damage to the maternal organ. Preeclampsia is commonly considered to result from the presence of a poor placenta since the only effective cure of the clinical syndrome is delivery of the placenta. Placenta occurs from weeks 6 to 18 of gestation, during which extravillous cytotrophoblast invasion is required for extensive remodeling of maternal spiral arteries [4]. In preeclampsia, placenta is extremely
shallow because of inadequate trophoblast invasion and deficient remodeling of spiral arteries [5, 6]. Implantation failure of placenta predisposes it to hypoxia and oxidative stress [7], thus resulting in a maternal systemic inflammatory response characterized by enhanced expression of inflammatory mediators [5]. It was found that dysfunctional placenta can release adverse factors into the maternal circulation, causing the clinical features of this condition. These factors include some hormones or chemical substances, such as sFlt1 (soluble fms-like tyrosine kinase 1) [4], AT1-AA (angiotensin II AT1 receptor auto-antibody) [6], and cardiac glycosides (marinobufagenin, MBG) [8]. Among these, sFlt1 can cause endothelial dysfunction in the maternal blood vessels by binding vascular endothelial growth factors and placental growth factor [4]; AT1-AA can react with the AT1 receptor in a stimulatory fashion similar to angiotensin II (RAS), 1,25-dihydroxyvitamin D (1,25(OH)2D3), and lipoxin A4. Evidence indicates that aberration in them may disrupt placenta development, contributing to adverse pregnancy outcome, such as preeclampsia (described subsequently). V-ATPase, another key molecule in placenta, is closely associated with all of them. During normal pregnancy, RAS, 1,25(OH)2D3, and lipoxin A4 may work independently, in parallel or jointly on the central molecule, V-ATPase, while V-ATPase also affects them at the same time. Therefore, the intriguing molecule V-ATPase may represent a key link between various causes of preeclampsia. In the following present review will focus on some new findings about interaction between V-ATPase and RAS, 1,25(OH)2D3 and lipoxin A4 in pregnancy, which will provide new insights into the molecular mechanisms underlying preeclampsia.

### 2. Vacuolar ATPase

The acidity regulation of intracellular and extracellular environment is crucial for a variety of biological processes, including acidity homeostasis, membrane trafficking, protein degradation, and sperm maturation [14]. Central to this regulation is the Vacuolar ATPase (V-ATPase), which is a large multisubunit complex functioning as an ATP-driven proton pump. V-ATPase is of significant importance in basic physiological processes, and it has been implicated in a number of human diseases, such as renal disease, tumour metastasis, and bone disease [14]. V-ATPase is composed of two large domains, V0 and V1. The V0 domain is a 260 kDa membrane-embedded complex that contains six different subunits (a, d, e, c, c', and c") and functions as
Stage 1
(preclinical stage)
Abnormal immune responses
(i.e. maternal immune rejection, Th1/Th2 imbalance, incorrect T cell recognition, unusual NK cell phenotype)
Disturbed endocrine system
(i.e. reduced level of RAS, progesterone and estrogen)
Defective placenta
(ischemia, hypoxia, oxidative stress)

Stage 2
(clinical stage)
Reduced blood supply
Release of placental factors (i.e. sFlt-1)
Fetal effects
(i.e. IUGR)
Maternal systemic inflammatory response
Endothelial dysfunction
Clinical manifestation of preeclampsia

**Figure 1:** Abnormal immune responses and endocrine system in the development of preeclampsia. Preclinical stage 1 occurs in early pregnancy when abnormal immune responses and disturbed endocrine system lead to poor placentation resulting in placental hypoxia, ischemia and oxidative stress. Clinical stage 2 occurs systemically when a defective placenta releases factors into the maternal circulation, which cause the maternal systemic inflammatory response and endothelial dysfunction that lead to the clinical signs of preeclampsia.

A proton-translocation domain, whereas the V1 domain is a 650 kDa cytoplasmic complex that contains eight different subunits (A, B, C, D, E, F, G, and H) and functions as an ATP-hydrolytic domain. It is the structural complexity of V-ATPase that makes it an important player in various physiological functions. Many of V-ATPase subunits have multiple isoforms, and so specific V-ATPase can be composed of different combinations of these subunit isoforms.

V-ATPase, mediating various physiological processes and cellular homeostasis, may be closely involved in different stages of reproduction. In fact, there are many reports demonstrating that V-ATPase has an important role in all aspects of mammalian reproduction, such as spermatogenesis, fertilization, embryonic implantation, and embryo development [15]. On one hand, the acidic microenvironment regulated by V-ATPase is essential for embryonic development following embryonic implantation. On the other hand, different V-ATPase has specific tissue distribution in reproduction system and exerts differential crucial function. Among all of the V-ATPase subunits, subunit “a” is involved in acrosomal reaction of sperm and embryonic implantation, both of which provide vital foundation for successful pregnancy [15]. Subunit “a” is a large membrane-spanning protein with a hydrophilic cytoplasmic N-terminal domain and a nine-transmembrane C-terminal domain [14], and it contains the information necessary to target the V-ATPase to different cellular destinations and is responsible for proton transport into the lumen of intracellular vesicles or across membranes [16]. There are four isoforms of subunit “a” (a1, a2, a3, and a4), which exhibit diverse tissue distribution and subcellular location [16]. Isoform 2 of subunit “a” (ATP6V0A2, referred to as a2V-ATPase) can be detected in the epididymis, kidney, lung, thymus, spleen, and placenta [17]. Recently, increasing evidence indicates the crucial role of a2V-ATPase in placental immune modulation associated with pregnancy [15]. In early pregnancy, many important cytokines secreted by placenta trophoblast cells and immune cells in decidua play a key role in embryonic implantation and fetomaternal immune tolerance [18]. Interestingly, it is reported that a2V-ATPase is important in controlling the expression of these essential cytokines [18]. Thus, the normal expression and localization of a2V-ATPase in fetoplacental unit is essential for pregnancy. Jaiswal et al. have reported that placental a2V-ATPase expression is a link between multiple causes of spontaneous abortion in mice, and dysfunction of a2V-ATPase in early pregnancy has been associated not only with spontaneous abortion but also with preeclampsia and fetal growth restriction [19]. Another interesting study found that NOX2/NADPH oxidase regulates antigen crosspresentation in adaptive immunity through changing phagosome lumen pH, whereas the effect of NOX2/NADPH oxidase on phagosomal pH is antagonized by V-ATPase, which may represent a novel mechanism responsible for the maintenance of immune tolerance [20]. Taken together, these indicate the importance of V-ATPase in maintaining reproduction process and placentation and modulating fetomaternal immune tolerance in pregnancy, whereas defective V-ATPase may increase the risk of causing a poor placenta and inducing preeclampsia (Figure 2).


The circulating renin-angiotensin system (RAS) is an endocrine hormone system that plays a key role in regulating blood pressure and systemic electrolyte balance. Apart from systemic circulating RAS, local RAS is present in many
tissues or organs, such as brain, heart, ovary, and placenta, and one of the major extrarenal RAS during pregnancy is the placental RAS [21]. In pregnancy, the circulating RAS maintains maternal electrolyte balance and blood pressure homeostasis, facilitating expanding blood supply for fetus, while the placental RAS has indispensable role in the utero-placental unit [21]. Components of placental RAS have been confirmed to be involved in many molecular events of placental establishment. A recent review reported that placental cytotrophoblast is rich in AT1 receptor, and ANG II-AT1 receptor signaling regulates multiple genes associated with normal trophoblast invasion, such as plasminogen activator inhibitor-1 (PAI-1), such as soluble fms-like tyrosine receptor-1 (sFlt-1) and soluble endoglin (s-Eng) [22]. Additionally, ANG II signaling also activates NF-kappa B and stimulates the synthesis of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase by trophoblast [22]. Moreover, it has been demonstrated by a recent study that activation of mineralocorticoid receptor in placental trophoblast by maternal aldosterone appears to be required for trophoblast growth and normal fetoplacental function [11]. Therefore, in response to pregnancy, both systemic RAS and placental RAS need to be adapted to sustain a healthy pregnancy.

Advances have revealed that maternal RAS is perturbed in preeclampsia. In an uncomplicated pregnancy, there is an increase in almost all the components of maternal RAS, including renin, angiotensin, and aldosterone, but these hormones are suppressed in preeclampsia [9]. However, the changes happening in the components of uteroplacental RAS are different from those observed in circulating RAS. Recent studies demonstrated that upregulation of the AT1 receptor expression [23], increase in renin level [24], and enhancement of ANG II production [25] occur in uteroplacental unit of preeclamptic women. So, the expression profile of both systemic RAS and placental RAS in preeclampsia differs greatly from that of healthy uncomplicated pregnancy. Additionally, there is a growing body of reports indicating the presence of the angiotensin II type I receptor agonistic autoantibody (AT1-AA) in preeclamptic women, and this autoantibody through AT1 receptor signaling can result in dysregulation of the RAS, then leading to clinical features of preeclampsia [22]. All abnormalities in both systemic RAS and placental RAS can cause poor placentation and preeclampsia.

There is accumulating evidence suggesting that components of RAS are interrelated to V-ATPase and are essential for regulating V-ATPase activity. The (pro)renin receptor ((P)RR), encoded in ATP6AP2, plays a key role in activation of the local RAS, while a truncated form of (P)RR, termed M8.9, was found to be associated with the V-ATPase assembly and function, implicating a novel role of (P)RR in V-ATPase activity [26]. Recently, another interesting report indicated that (P)RR functions as an adaptor between Wnt receptor and V-ATPase, which is required for mediating Wnt signaling [27]. It was found that angiotensin II has profound effects on H+ transport and urinary acidification in kidney, mainly through its regulation on V-ATPase activity, and it has also been confirmed to stimulate vacuolar H+-ATPase activity in renal acid-secretory intercalated cells from the outer medullary collecting duct [28]. Not long before, a report showed that aldosterone may participate in the regulation of V-ATPase activity in acid-secretory intercalated cells through rapid nongenomic stimulatory action and contribute to urinary acidification [29]. Meanwhile, another study, prior to this review, described that aldosterone has both genomic and nongenomic stimulatory effects on V-ATPase in proximal S3 segments [30]. Considering the content described earlier, it is reasonable that uteroplacental V-ATPase function is a key link between RAS and placentation. Therefore, any aberration in interaction between RAS and V-ATPase may induce preeclampsia by interfering various processes in placental development.

**Figure 2:** Abnormal V-ATPase function in the development of preeclampsia. Preclinical stage of preeclampsia occurs in early pregnancy when dysfunctional V-ATPase activity leads to deficient embryonic implantation, abnormal placentation development and fetomaternal immune intolerance, resulting in poor placenta. Clinical stage of preeclampsia occurs systemically when a defective placenta causes the maternal systemic inflammatory response and endothelial dysfunction that lead to the clinical signs of preeclampsia.

**4. 1,25-Dihydroxyvitamin D, V-ATPase, and Preeclampsia**

1,25-Dihydroxyvitamin D (1,25(OH)2D3), the active form of vitamin D, has long been considered to be a leading molecule in calcium and bone homeostasis. However, in the past years, it was found that vitamin D receptor (VDR) is present in most tissues and many tissues contain the 1,25(OH)2D3 synthase, 25(OH)D3-1-

\[ \alpha \]

hydroxylase [31, 32], which makes us begin to be aware of multiple nonclassic actions of 1,25(OH)2D3. In fact, advances have shown that 1,25(OH)2D3 deficiency may increase the risk of developing a wide range of chronic diseases, including cancer, autoimmune disease, infectious...
immune cells, such as macrophage, dendritic cell, activated the kidney, 1,25(OH)2D3 can also be locally produced by class I molecules, CD40, CD80, and CD86. A recent study by Halmali et al demonstrated that the level of 1,25(OH)2D3 in both maternal circulation and umbilical cord compartment is low in preeclampsia. Furthermore, expression and activity of 25-hydroxyvitamin D-1α-hydroxylase has been confirmed to be significantly restricted in placentas of preeclamptic pregnancy. So, 1,25(OH)2D3 insufficiency during pregnancy is potentially associated with increased risk of preeclampsia.

Typical feature of preeclampsia is maternal systemic inflammatory response, characterized by upregulation of proinflammatory mediators in both uteroplacental unit and peripheral circulation. In fact, as described previously, the systemic inflammatory response in preeclampsia is thought to stem from initial disorder of fetomaternal immune tolerance. Vitamin D, particularly 1,25(OH)2D3, has received general and basic pathogenesis of preeclampsia. Indeed, a clinical study by Saito speculated that imbalance between regulatory T cells and Th17 cell is suppressed by 1,25(OH)2D3. In summary, maternal vitamin D deficiency may trigger preeclampsia through several forms of cell stress including hypoxia, infection, and starvation. If autophagy could not be initiated properly, disturbance in autophagy will result in a wide range of disorder. In the case of preeclampsia, abnormal placentation in early pregnancy predisposes placenta ischemia, hypoxia, and oxidative stress, which accumulates large numbers of apoptotic trophoblast cells at uteroplacental interface. If not treated through cell autophagy, the apoptotic trophoblast cells may impair further placenta development seriously and induce onset of preeclampsia. Thus, maternal vitamin D deficiency may trigger preeclampsia through affecting V-ATPase activity, which seems to represent a general and basic pathogenesis of preeclampsia.

5. Lipoxin A4, V-ATPase, and Preeclampsia

There is an intimate interaction between vitamin D and V-ATPase. Indeed, a recent study demonstrated that in the presence of vitamin D, human osteoclasts express elevated V-ATPase levels. Meanwhile, this work also described that 1,25(OH)2D3 can upregulate the activity of V-ATPase complex. Although the study did not study the case in pregnancy, it will imply us that 1,25(OH)2D3 may have an important effect on uteroplacental V-ATPase activity. Moreover, the ability of 1,25(OH)2D3 to regulate secretion of pregnancy-related hormones may explain its role in mediating V-ATPase activity. 1,25(OH)2D3 has been confirmed to be an important player in the upregulation of estrogen biosynthesis, and the previous description has also revealed that V-ATPase expression is estrogen dependent, which makes it reasonable to speculate that 1,25(OH)2D3 can act on V-ATPase indirectly by influencing hormones level. Recently, a significative review suggested that autophagy is a general basis for the multiple health-promoting effects of vitamin D. Autophagy, depending on lyosomal self-digestion machinery, is an evolutionarily conserved self-catabolism process that is essential for cell growth, development, and homeostasis. To a great extent, V-ATPase is vital for autophagy since V-ATPase is of great importance for lysosomal function. Thus, coupled with V-ATPase, 1,25(OH)2D3 could induce and activate autophagy, protecting human against many diseases. Autophagy is induced by several forms of cell stress including hypoxia, infection, and starvation. If autophagy could not be initiated properly, disturbance in autophagy will result in a wide range of disorder. In the case of preeclampsia, abnormal placentation in early pregnancy predisposes placenta ischemia, hypoxia, and oxidative stress, which accumulates large numbers of apoptotic trophoblast cells at uteroplacental interface. If not treated through cell autophagy, the apoptotic trophoblast cells may impair further placenta development seriously and induce onset of preeclampsia. Thus, maternal vitamin D deficiency may trigger preeclampsia through affecting V-ATPase activity, which seems to represent a general and basic pathogenesis of preeclampsia.

Lipoxin, the “stop signal” for inflammation, is the first mediator recognized to have dual anti-inflammatory and proresolution activities. In mammals, lipoxin A4 is the major lipoxin that has potent actions in vivo. Lipoxin A4, mainly depending on transcellular biosynthesis in the inflammation microenvironment, is derived from arachidonic acid by the sequential action of lipoxygenase (LOX). Leukocyte/platelet interaction, involving two key enzymes 5-LOX and 12-LOX, is one of the most important synthesis forms. This pattern of biosynthesis involves the initiation of arachidonic acid oxygenation by 5-LOX in leukocytes, and then the intermediate leukotriene A4 is converted into lipoxin A4 by 12-LOX in platelets. Interestingly, our previous results indicated that platelet-derived microparticles containing 12-LOX can be transferred to leukotriene-producing mast cells, which represents a new pathway for lipoxin A4 biosynthesis in vivo.
Lipoxin A4 can act on many cell types including blood cell, neural cell, and stromal cell [44]. Lipoxin A4 displays selective regulation for leukocyte responses and trafficking in vivo through activating its specific receptor, ALXR. For example, in neutrophils, lipoxin A4–ALXR interaction blocks neutrophil migration and infiltration into sites of inflammation. By contrast, in monocytes, LXA4–ALXR interaction stimulates monocyte recruitment and the phagocytosis of apoptotic neutrophils. Recently, we found that lipoxin A4 can suppress hepatocellular carcinoma via remodeling tumor microenvironment [46]. Moreover, we found that ALXR (also termed FPR2) has an appreciable pleiotropic regulator role in macrophage polarization, and LXA4–induced M2a+M2c-like macrophage phenotype showed antitumorigenesis activities [47]. Taken together, all previous results show us the key role of lipoxin A4 as an essential modulator of immune response and homoeostasis.

Inflammatory processes are central to a series of pregnancy events, while inflammation dysregulation is a typical feature of pregnant complications, such as preeclampsia and preterm. Normal pregnancy is characterised by a state of mild maternal systemic inflammation, which develops when pregnancy is progressing [5]. Although preeclampsia is also associated with inflammatory response, it is an exaggerated maternal systemic inflammatory response [6]. In fact, this disorder is an extreme condition of a range of uncontrolled inflammatory responses induced by abnormal pregnancy. Lipoxin A4, as an anti-inflammatory and proresolution mediator, will play an important role in human pregnancy. In fact, level of lipoxin A4 in nonpregnant women is significantly lower than that in pregnant women, and circulating level of lipoxin A4 in pregnant women displayed a modest but significant increase throughout pregnancy [48]. Thus, it is tempting to speculate that inadequate production of lipoxin A4 can lead to abnormality of placental immunomicroenviroment, increasing the risk of preeclampsia. This has been confirmed by our results from clinical study that level of lipoxin A4 in preeclampsia is significantly lower than that in normal pregnancy. Additionally, our results from animal study demonstrated that lipoxin A4 could suppress the increased production of proinflammatory cytokines and alleviate the symptoms of preeclampsia in LPS-induced rat model for human preeclampsia [49]. Moreover, results from our previous study verified that lipoxin A4 can inhibit the enhanced IL-1β production of monocytes from severe preeclampsia women [50]. Recently, preliminary results from animal study indicated that lipoxin A4 may participate in the regulation of maternal systemic immune tolerance in early pregnancy. Therefore, lipoxin A4, an endogenous anti-inflammatory and proresolution mediator, is a key player in terminating maternal systemic homoeostasis in pregnancy.

There exists an interrelationship between lipoxin A4 and V-ATPase. In fact, this is the case. The recent findings by Russell et al. found that lipoxin A4 is a novel estrogen receptor modulator and exhibits estrogenic activity in vivo, revealing a previously unappreciated facet of various bioactions of this anti-inflammatory and pro-resolution mediator [51]. Thus, lipoxin A4 may exert an important role in regulating the V-ATPase expression, as V-ATPase expression level is estrogen dependent, which has been mentioned earlier in this review. In addition, V-ATPase may also participate in the modulation of lipoxin A4 bioactions. There is evidence implicating that V-ATPase may get involved in the complex interaction between lipoxin A4 and its receptor in lipoxin A4-stimulated signal pathways. Maderna et al. reported that internalization and trafficking is critical for LXA4-stimulated phagocytosis in the resolution of inflammation [52]. Transmembrane receptors internalization is of physiological importance, which is required for right signal transduction, proper dissociation of ligand from receptor, and receptor-mediated endocytosis. Although receptor internalization may occur in different ways, V-ATPase-mediated intraendosomal pathway is the main endocytic trafficking machinery [53]. Therefore, internalization and trafficking of lipoxin A4 receptor is likely to require the right assembly and activity of V-ATPase in the endocytic complex of ALXR internalization. If there is some defect in V-ATPase, biological actions of LXA4 through ALXR could be severely hindered. In summary, lipoxin A4 may play an important role in modulating V-ATPase activity during pregnancy while the key role of lipoxin A4 in fetomaternal immunoregulation also depends on normal V-ATPase activity extensively.

6. Proposed Model and Conclusion

Based on the previous novel findings, a model of how placental V-ATPase function can be a key link between multiple causes of preeclampsia is proposed (Figure 3). On one hand, V-ATPase is an essential modulator in regulating bioaction of RAS, 1,25(OH)2D3, and lipoxin A4 during pregnancy. On the other hand, key roles of RAS, 1,25(OH)2D3, and lipoxin A4 can be integrated into the V-ATPase function in pregnancy. Right cross-talk between V-ATPase and RAS, 1,25(OH)2D3, and lipoxin A4 can facilitate normal placentation and ensure successful pregnancy. Once disorder of V-ATPase activity takes place at the fetomaternal interface, various bioactivity of RAS, 1,25(OH)2D3, and lipoxin A4 will come into great trouble, and vice versa. Any abnormality occurring at the interaction between V-ATPase and RAS, 1,25(OH)2D3 and
lipoxin A4 could cause a defective placenta, which will be eventually involved in the progression of preeclampsia. Overall, the previous proposal not only suggests the importance of V-ATPase in modulating essential components of maternal endocrine system (RAS) and key molecules of fetomaternal immune interaction (1,25(OH)2D3 and lipoxin A4), but also shows the key role of RAS, 1,25(OH)2D3, and lipoxin A4 in regulating V-ATPase function.

Almost all cases of preeclampsia are associated with poor placentation. Maternal endocrine system and immune responses have been long considered to be involved in normal placenta development. The renin-angiotensin system is a typical endocrine hormone system that plays a key role in regulating placenta as well as maintaining normal pregnancy. Recently, the immunomodulation of vitamin D in pregnancy has been proposed as a key aspect of placental homoeostasis. Additionally, lipoxin A4, as an anti-inflammatory and proresolution mediator, has been demonstrated to be vital in modulating fetomaternal immune tolerance during pregnancy. Nevertheless, the complexity of various molecular events that occur at the fetomaternal interface in placenta development is far from being completely elucidated. A series of molecular mechanisms needs to be coordinated for establishing a perfect placenta, while any deviation from this ordered course of molecular events may result in pregnancy complications, such as preeclampsia. V-ATPase, a key molecule in placentation, is beginning to be appreciated. It is closely linked to renin-angiotensin system, 1,25(OH)2D3, and lipoxin A4. Therefore, it may work as a key link between multiple causes of preeclampsia. Further studies regarding V-ATPase-related molecular mechanisms necessary for placentation are required, since clinical intervention to these potential dysregulated molecular events may eventually improve pregnancy outcome.

6.1. Further Research Directions

(1) Determine the detailed role of V-ATPase in fetoplacental unit.
(2) Clarify the potential role of placental V-ATPase in preeclampsia.
(3) Investigate the nature of interaction between V-ATPase and RAS, 1,25(OH)2D3, and lipoxin A4 in normal pregnancy.
(4) Investigate the causes of abnormal interaction between V-ATPase and RAS, 1,25(OH)2D3, and lipoxin A4 in preeclampsia.
(5) Understand the mechanisms of placental damage associated with defective V-ATPase, RAS, 1,25(OH)2D3 and lipoxin A4 in preeclampsia.
(6) Study the effect of potential therapeutic agents on placental damage and maternal clinical signs of preeclampsia.

Conflict of Interests

There is no conflict of interests.

Acknowledgments

This work was supported by National Natural Science Foundation of China Grants 81070510, 81171495 and 81271765.

References


and possible mechanisms,” *Reproductive Toxicology*, vol. 34, no. 4, pp. 677–685, 2012.


